Oral adverse drug reactions in precision oncology: A phenotype-first framework for causality, triage, and treatment continuity

Introduction: Precision oncology has broadened the spectrum of oral adverse drug reactions (ADRs), while combination regimens and common oral diseases complicate their recognition and attribution. Objectives: To propose a phenotype-first framework for assessing suspected oral ADRs, guiding triage and management, and supporting anticancer treatment continuity. Methods: A manual literature search was conducted in PubMed/MEDLINE and Google Scholar using combinations of keywords such as “oral adverse drug reactions,” “oral toxicity,” “precision oncology,” “immune checkpoint inhibitors,” “targeted therapy,” “oral mucositis,” “xerostomia,” “medication-related osteonecrosis of the jaw,” “oral lichenoid reactions,” and “supportive care.” Relevant studies and clinical guidelines were synthesized narratively to develop a phenotype-first framework. Results: The framework considers lesion morphology and functional impact alongside treatment chronology, host factors, local dental conditions, targeted investigations, and response to intervention. It addresses immune-inflammatory and lichenoid disease, aphthous-like or mucositis-like ulceration, salivary and taste dysfunction, secondary infection, and impaired wound or bone healing. Combining phenotype with diagnostic certainty and clinical severity informs proportionate action, from local supportive care and reassessment to urgent specialist evaluation and oncology coordination. Structured documentation and patient-reported outcomes can support longitudinal assessment and pharmacovigilance. Conclusion: Phenotype-first reasoning may help clinicians distinguish suspected treatment toxicity from competing or coexisting oral conditions and manage reversible symptoms without unnecessarily disrupting cancer therapy. Severe, persistent, atypical, or diagnostically uncertain findings require timely interdisciplinary assessment. Prospective evaluation is needed to establish the framework’s reproducibility and clinical utility.

Authors

Publication Details

Journal
Eurasian Journal of Medicine and Oncology
Published
2026-11-16
DOI
https://doi.org/10.36922/ejmo026330429
Primary Topic
Oral health in cancer treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Oral adverse drug reactions in precision oncology: A phenotype-first framework for causality, triage, and treatment continuity

Alessandro Polizzi, Giorgia Maria Marmo, Gaetano Isola, Angela Angjelova et al.
Eurasian Journal of Medicine and Oncology
Oral health in cancer treatment
article

Oral adverse drug reactions in precision oncology: A phenotype-first framework for causality, triage, and treatment continuity

Alessandro Polizzi, Giorgia Maria Marmo, Gaetano Isola, Angela Angjelova, Elena Jovanova, Roberto Campagna
article en

Abstract

Introduction: Precision oncology has broadened the spectrum of oral adverse drug reactions (ADRs), while combination regimens and common oral diseases complicate their recognition and attribution. Objectives: To propose a phenotype-first framework for assessing suspected oral ADRs, guiding triage and management, and supporting anticancer treatment continuity. Methods: A manual literature search was conducted in PubMed/MEDLINE and Google Scholar using combinations of keywords such as “oral adverse drug reactions,” “oral toxicity,” “precision oncology,” “immune checkpoint inhibitors,” “targeted therapy,” “oral mucositis,” “xerostomia,” “medication-related osteonecrosis of the jaw,” “oral lichenoid reactions,” and “supportive care.” Relevant studies and clinical guidelines were synthesized narratively to develop a phenotype-first framework. Results: The framework considers lesion morphology and functional impact alongside treatment chronology, host factors, local dental conditions, targeted investigations, and response to intervention. It addresses immune-inflammatory and lichenoid disease, aphthous-like or mucositis-like ulceration, salivary and taste dysfunction, secondary infection, and impaired wound or bone healing. Combining phenotype with diagnostic certainty and clinical severity informs proportionate action, from local supportive care and reassessment to urgent specialist evaluation and oncology coordination. Structured documentation and patient-reported outcomes can support longitudinal assessment and pharmacovigilance. Conclusion: Phenotype-first reasoning may help clinicians distinguish suspected treatment toxicity from competing or coexisting oral conditions and manage reversible symptoms without unnecessarily disrupting cancer therapy. Severe, persistent, atypical, or diagnostically uncertain findings require timely interdisciplinary assessment. Prospective evaluation is needed to establish the framework’s reproducibility and clinical utility.

Eurasian Journal of Medicine and OncologyVol. 0(0)
Oral health in cancer treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon